Tag results:

NSCLC

FOXP3 Activated-LINC01232 Accelerates the Stemness of Non-Small Cell Lung Carcinoma by Activating TGF-β Signaling Pathway and Recruiting IGF2BP2 to Stabilize TGFBR1

[Experimental Cell Research] Flow cytometry and sphere formation assays indicated that LINC01232 significantly promoted non-small cell lung carcinoma cell stemness.

PLOD3 Regulates the Expression of YAP1 to Affect the Progression of Non-Small Cell Lung Cancer via the PKCδ/CDK1/LIMD1 Signaling Pathway

[Laboratory Investigation] Silencing procollagen-lysine, 2-oxoglutarate 5-dioxygenase (PLOD3) promoted the cleavage ofprotein kinase C δ (PKCδ) in a caspase-dependent manner to generate a catalytically active fragment cleaved PKCδ, enhanced phosphorylation levels of CDK1, and LIMD1 but suppressed nuclear translocation of YAP1.

Breaking the Crosstalk of the Cellular Tumorigenic Network by Low-Dose Combination Therapy in Lung Cancer Patient-Derived Xenografts

[Communications Biology] Selecting drug combinations for overcoming resistances, NSCLC patient-derived xenograft tumors were treated with a low dose combination of cabozantinib, afatinib, plerixafor and etoricoxib.

Integrated Single-Cell RNA Sequencing Analysis Reveals Distinct Cellular and Transcriptional Modules Associated with Survival in Lung Cancer

[Signal Transduction and Targeted Therapy] Researchers established a multi-omics atlas, integrating 52 single-cell RNA sequencing and 2342 public bulk RNA sequencing. They investigated their differences in genetic amplification, cellular compositions, and expression modules.

EDDM3A Drives Gastric Cancer Progression by Promoting HIF-1α-Dependent Aerobic Glycolysis

[Oncogenesis] Researchers showed that the expression of EDDM3A was significantly upregulated in gastric cancer tissues and its upregulation correlates with poorer survival in patients with gastric cancer.

Rubius Therapeutics Announces Dosing of First Patient in Phase I/II Trial of RTX-224, a Broad Immune Agonist, for the Treatment of Certain Solid Tumors

[Rubius Therapeutics, Inc.] Rubius Therapeutics, Inc. announced that the first patient has been dosed in its Phase I/II clinical trial of RTX-224 for the treatment of patients with certain relapsed/refractory or locally advanced solid tumors, including non-small cell lung cancer, cutaneous melanoma, head and neck squamous cell carcinoma, urothelia carcinoma and triple-negative breast cancer.

Popular